鏀惰棌-鍋ュ悍緗戜細鍛樿闂褰?/h3>

緗戦〉鏍囬錛?

娉ㄥ唽鍋ュ悍緗戠敤鎴?/h3>

鐢?鎴?鍚嶏細
鑱?緋?浜猴細
鎬?nbsp; 鍒細
瀵?nbsp; 鐮侊細
閲嶅瀵嗙爜錛?/th>
鐢靛瓙閭錛?/th>
閭楠岃瘉鐮侊細
鍥哄畾鐢佃瘽錛?/th>
浼?nbsp; 鐪燂細
鎵?nbsp; 鏈猴細
鍗曚綅鍚嶇О錛?/th>
閫氫俊鍦板潃錛?/th>
棣栭€夋爮鐩細
鎴戝凡緇忚鐪熼槄璇誨茍鍚屾剰銆婂仴搴風綉鏈嶅姟鏉℃銆?/a>

鎵懼洖瀵嗙爜

  • 1.閫夋嫨鎵懼洖鏂瑰紡
  • 2.紜楠岃瘉淇℃伅
  • 3.淇敼瀵嗙爜
  • 4.淇敼鎴愬姛
  • 鎵懼洖鏂瑰紡錛?/span>
  • 鐢?鎴?鍚嶏細
  • 鎵嬫満鍙風爜錛?/span>
涓撻鏍忕洰錛?

鐮旂┒鎶ュ憡鎼滅儲錛?

 鎮ㄧ幇鍦ㄤ綅緗細鍋ュ悍緗?鍖昏嵂浜т笟 >> 鐮旂┒鎶ュ憡 >> English reports >> English reports >> 嫻忚鍖昏嵂琛屼笟鐮旂┒鎶ュ憡

Market Report of Monoclonal Antibody Drugs in China (2022)

浣滆€咃細leigy   鏉ユ簮錛氭湰绔欏師鍒?nbsp;   鐐瑰嚮鏁幫細0    鏇存柊鏃墮棿錛?022-9-20 9:13:54

[鍏抽敭瀛梋錛?/font> mAb PD-1 ADC BsAb CTLA-4 DS-8201 BeiGene RemeGen Akeso TopAlliance Innovent Henlius Pembrolizumab "Keytruda"

鍋ュ悍緗戣錛?/FONT>

  Report Title: Market Report of Monoclonal Antibody Drugs in China (2022)

  date: Sep, 2022

  Format:  Adobe PDF

  Price:  $ 9,900

        錕?61,800

  Contact: Leo. (Mr. Lei Guangyu) / Ms. Xue zhe

  Tel: 86-10-68012929-2103/2113

  Mobile: 86-13810934380

  E-mail: leigy@healthoo.com


Monoclonal Antibody(mAb) drugs is the largest category of products in the biopharmaceutical industry. This report makes detailed statistics
analysis on the scale growth rate of domestic market, sales volume price trends, competitions, etc. of mAb in various treatment fields and 
different target categories in the past five years.

In recent years, the development marketing of monoclonal antibody drugs have increased rapidly. The number of monoclonal antibody drugs approved in China has increased from 13 in 2017 to 60 in 2022.

image.png

Graph 2 Number of mAB drugs listed in China from 2017 to July 2022

At present, monoclonal antibodies are mainly used in ten therapeutic fields, of which 33 are used for anti-tumor, 15 for rheumatoid other

autoimmune diseases, 3 for fundus maculopathy 2 for cholesterol lowering.

Table 4 Number of mAB drugs listed in China distribution of treatment fields from 2017 to July 2022

image.png

Monoclonal antibody drugs used in the field of anti-tumor therapy can be classified into four categories based on their mechanism of action market characteristics. One category is the traditional drugs targeting tumor related molecules, which can be classified into two sub 
categories: inhibiting the key molecules of tumor survival, activating the innate adaptive immunity against tumors. The other three are the 
most popular categories in recent years: immune checkpoint inhibitors, ADC (Antibody-drug conjugates) Bispecific antibody(BsAb) drugs. 

Table 8 Number of mAB for anti-tumor in China from 2017 to July 2022

image.png

Brentuximab Vedotin for injection is a mAB against CD38. It is the world's first ADC drug developed by Seagen Takeda in 2011. Its brname is 鈥淎dcetris鈥? It is sold by Takeda outside North America.

In 2020, Brentuximab vedotin imported into China for the treatment of lymphoma, which is the most successful commercial ADC drug in the 
field of blood tumor treatment. The specification is 50mg, the price decreased from 22,362 yuan/piece in 2020 to 16,860 yuan in 2021.

However, the negotiation of medical insurance has not been successful.


image.png

Graph 19 Sales volume price comparison of Brentuximab Vedotin for injection from 2020 to 2021

image.png

image.png

image.png

image.png

image.png

image.png

image.png

image.png

image.png

Market Report of Monoclonal Antibody Drugs in China (2022)
娉ㄥ唽鍚?鎴戜滑浼氫負浣犳彁渚涙姤鍛婃牱鏈茍涓烘偍鎻愪緵鏇村叏闈㈢殑鍜ㄨ鏈嶅姟
鎮ㄧ殑濮撳悕  縐拌皳: 鍏堢敓濂沖+
鎵嬫満鍙風爜 
鐢靛瓙閭歡 
鍗曚綅鍚嶇О 

鏈嶅姟鐑嚎

  • 鑱旂郴欏圭洰錛?span>86-10-68012929-2103
  • 璁㈣喘鎶ュ憡錛?span>86-10-68012929-2103
  • 閭歡璁㈣喘錛?span>leigy@healthoo.com
久久精品国产亚洲AV麻豆导航 欧美一区二区三区视频在线观看 无码免费婬AA片在线电影网站 国产女人激烈高潮抽搐免费观看